Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5608
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis ; volume:25 ; number:2 ; day:30 ; month:5 ; year:2021 ; pages:139-148 ; date:6.2022
Prostate cancer and prostatic diseases ; 25, Heft 2 (30.5.2021), 139-148, 6.2022
- Creator
-
Wenzel, Mike
Nocera, Luigi
Collà Ruvolo, Claudia
Würnschimmel, Christoph
Tian, Zhe
Shariat, Shahrokh F.
Saad, Fred
Tilki, Derya
Graefen, Markus
Kluth, Luis
Briganti, Alberto
Mandel, Philipp
Montorsi, Francesco
Chun, Felix
Karakiewicz, Pierre I.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41391-021-00395-4
- URN
-
urn:nbn:de:101:1-2022082321063896180286
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wenzel, Mike
- Nocera, Luigi
- Collà Ruvolo, Claudia
- Würnschimmel, Christoph
- Tian, Zhe
- Shariat, Shahrokh F.
- Saad, Fred
- Tilki, Derya
- Graefen, Markus
- Kluth, Luis
- Briganti, Alberto
- Mandel, Philipp
- Montorsi, Francesco
- Chun, Felix
- Karakiewicz, Pierre I.
- SpringerLink (Online service)
Other Objects (12)
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Editorial Comment to Testicular cancer and YouTube: What do you expect from a social media platform?
Beurteilung des Einflusses von Sirolimus und Everolimus auf den Ischämie-Reperfusionsschaden im humanen Gefäßmodell
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
Chemotherapie ± Androgenrezeptorantagonisten beim metastasierten hormonsensitiven Prostatakarzinom
Aktueller Behandlungsstandard und Trends der Systemtherapie beim metastasierten hormonsensiblen Prostatakarzinom – Anwendung der Studiendaten in der Praxis
Diagnosis of clinically significant prostate cancer diagnosis without histological proof in the prostate-specific membrane antigen era: the jury is still out
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Editorial Comment to Testicular cancer and YouTube: What do you expect from a social media platform?
Beurteilung des Einflusses von Sirolimus und Everolimus auf den Ischämie-Reperfusionsschaden im humanen Gefäßmodell
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
Chemotherapie ± Androgenrezeptorantagonisten beim metastasierten hormonsensitiven Prostatakarzinom
Aktueller Behandlungsstandard und Trends der Systemtherapie beim metastasierten hormonsensiblen Prostatakarzinom – Anwendung der Studiendaten in der Praxis
Diagnosis of clinically significant prostate cancer diagnosis without histological proof in the prostate-specific membrane antigen era: the jury is still out
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Editorial Comment to Testicular cancer and YouTube: What do you expect from a social media platform?
Beurteilung des Einflusses von Sirolimus und Everolimus auf den Ischämie-Reperfusionsschaden im humanen Gefäßmodell
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
Chemotherapie ± Androgenrezeptorantagonisten beim metastasierten hormonsensitiven Prostatakarzinom
Aktueller Behandlungsstandard und Trends der Systemtherapie beim metastasierten hormonsensiblen Prostatakarzinom – Anwendung der Studiendaten in der Praxis